StockData
Disc Medicine, Inc. logo

Disc Medicine, Inc. (IRON) stock

IRONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$76.59−3.41 (-4.26%)

Close on Nov 16, 2026Market cap $2.94BP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$2.94B
P/E ratio
–
Price to sales
–
Price to book
4.56
Dividend yield
–
Free cash flow yield
-6.72%

Fundamentals

Net income
-$245.89M
EPS, diluted
-$6.57
Free cash flow
-$197.58M
Book value per share
$16.65
Diluted shares
39M

Trading

Next earnings
Feb 25, 2027 (estimated, before the open)
Previous close
$80.00
Open
$80.12
Day's range
$76.40 – $80.37
Volume
817,338
Average volume (20 days)
1,328,784
Index membership
Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
52-week range
$40.00 – $99.50
RSI (14 days)
49.1
Volatility (1 year)
63.6%
Relative volume
1.08×

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodIRONS&P 500DifferenceIRON per yearS&P 500 per year
1 month+34.7%-3.1%+37.8 pts
3 months-2.9%-4.5%+1.6 pts
Year to date-3.6%+9.4%−12.9 pts
1 year-14.9%+11.3%−26.2 pts
3 years+58.4%+70.4%−12.0 pts+16.6%+19.4%
5 years+95.4%+68.6%+26.8 pts+14.3%+11.0%

Seven years at a glance

Fiscal years 2019 to 2025 and trailing twelve months, USD

Operating income

-$269.27M

Net income

-$245.89M

EPS, diluted

-$6.57

Free cash flow

-$197.58M
Reported periodTrailing twelve months

Press releases

Releases Disc Medicine filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Disc Medicine

Pharmaceutical Preparations

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic treatments for patients suffering from serious hematologic conditions. The company focuses on biological mechanisms regulating red blood cell production and function, specifically targeting heme biosynthesis and iron homeostasis. Its development pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria and X-linked protoporphyria, DISC-0974 for anemia related to myelofibrosis and inflammatory bowel disease, and DISC-3405 for polycythemia vera and sickle cell disease. Additionally, the company is advancing a preclinical candidate, DISC-0998, for inflammatory anemia. Its target patient population consists of individuals with these blood disorders.

Company profile, executives and history

Disc Medicine stock: common questions

What is Disc Medicine's stock price?

IRON closed at $76.59 on Nov 16, 2026, down 4.26% on the day. Over the past 52 weeks it traded between $40.00 and $99.50.

What is Disc Medicine's market cap?

Disc Medicine was worth $2.94B at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is IRON's P/E ratio?

Disc Medicine lost money over the twelve months to Jun 30, 2026 (diluted EPS -$6.57), so it has no meaningful P/E ratio.

Does Disc Medicine pay a dividend?

No. Disc Medicine has not paid a cash dividend over the last twelve months.

When does Disc Medicine report earnings next?

Disc Medicine is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has IRON stock performed over the past year?

Including dividends, IRON returned -14.9% over the past year, against +11.3% for the S&P 500.

How many IRON shares are sold short?

7M shares were sold short at the latest FINRA report, 25.34% of the float, or 3.2 days of average trading volume.

Who are Disc Medicine's competitors?

Companies most similar to Disc Medicine by business, industry and size include DMRA, FULC, DMAC, KROS, AGIO.

See a number that looks wrong?